IL326916A - אורתולוגים חיידקיים של nme7 ושימושים בהם - Google Patents

אורתולוגים חיידקיים של nme7 ושימושים בהם

Info

Publication number
IL326916A
IL326916A IL326916A IL32691626A IL326916A IL 326916 A IL326916 A IL 326916A IL 326916 A IL326916 A IL 326916A IL 32691626 A IL32691626 A IL 32691626A IL 326916 A IL326916 A IL 326916A
Authority
IL
Israel
Prior art keywords
nme7
orthologs
bacterial
nme7 orthologs
bacterial nme7
Prior art date
Application number
IL326916A
Other languages
English (en)
Original Assignee
Minerva Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Biotechnologies Corp filed Critical Minerva Biotechnologies Corp
Publication of IL326916A publication Critical patent/IL326916A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001162—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL326916A 2023-08-29 2024-08-27 אורתולוגים חיידקיים של nme7 ושימושים בהם IL326916A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363579494P 2023-08-29 2023-08-29
PCT/US2024/044066 WO2025049494A1 (en) 2023-08-29 2024-08-27 Bacterial nme7 orthologs and uses thereof

Publications (1)

Publication Number Publication Date
IL326916A true IL326916A (he) 2026-05-01

Family

ID=92800091

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326916A IL326916A (he) 2023-08-29 2024-08-27 אורתולוגים חיידקיים של nme7 ושימושים בהם

Country Status (2)

Country Link
IL (1) IL326916A (he)
WO (1) WO2025049494A1 (he)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023201234A2 (en) 2022-04-12 2023-10-19 Minerva Biotechnologies Corporation Anti-variable muc1* antibodies and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014306778B2 (en) 2013-08-12 2020-10-29 Minerva Biotechnologies Corporation Method for enhancing tumor growth
TW201529596A (zh) * 2013-10-22 2015-08-01 Minerva Biotechnologies Corp 微生物之ｎｍｅ
CA2945162A1 (en) 2014-04-07 2015-10-15 Minerva Biotechnologies Corporation Use of an anti-nme antibody for treatment or prevention of cancer
EP3759145A4 (en) 2018-02-26 2022-03-09 Minerva Biotechnologies Corporation DIAGNOSTIC METHODS USING ANTI-MUC1* ANTIBODIES
AU2020219046A1 (en) 2019-02-04 2021-08-19 Minerva Biotechnologies Corporation Anti-NME antibody and method of treating cancer or cancer metastasis
CA3187555A1 (en) 2020-07-29 2022-02-03 Minerva Biotechnologies Corporation Anti-variable muc1* antibodies and uses thereof
WO2023201234A2 (en) 2022-04-12 2023-10-19 Minerva Biotechnologies Corporation Anti-variable muc1* antibodies and uses thereof

Also Published As

Publication number Publication date
WO2025049494A1 (en) 2025-03-06

Similar Documents

Publication Publication Date Title
AU2021447219A1 (en) Microorganisms and uses thereof
EP4165049A4 (en) ISOTRYPTAMIN PSYCOPLASTIOGENS AND USES THEREOF
GB202002010D0 (en) Microtopographies and uses thereof
EP4100031A4 (en) MICROBIAL COMBINATIONS AND USES THEREOF
EP4127178A4 (en) RECOMBINANT MICROORGANISMS AND METHOD
IL320918A (he) תכשירים מיקרוביאלים ושיטות
ZA202304231B (en) Recombinant microorganisms and uses therefor
IL308247A (he) חיידיקים מהמיקרוביוטה ושימושים שלהם
GB202211784D0 (en) Methods and uses
CA3242880A1 (en) COMBINATION OF OBITECRAPIB AND SGLT2 INHIBITOR
HK40103180A (en) Microorganisms and uses thereof
AU2021900518A0 (en) Bacteria conferring bioprotection and/or biofertilizer properties
CA3309906A1 (en) Auto-expression broth and uses thereof
HK40108849A (en) Nitrophenyl-acrylamides and uses thereof
GB202202916D0 (en) Enzymes and uses thereof
EP4199735A4 (en) MICROBES AND ANTIBIOTICS
HK40074609A (en) Biologically contained bacteria and uses thereof
HK40106466A (zh) Ert2突变体及其用途
HK40115042A (en) Lurbinectedin and atezolizumab combinations
CA3276902A1 (en) Substituted trianglamine and uses thereof
HK40110659A (zh) 去优化的sars-cov-2变异株及其方法和用途
AU2020900439A0 (en) Tpv-2l variants and uses thereof
AU2023901461A0 (en) AIPROPERTY and AIREALESTATE
GB202308562D0 (en) Novel methods and uses
AU2022903153A0 (en) Treatment methods and uses thereof